Latest Safety News

Hastings Technology Metals and JV partner Wyloo have unveiled an updated Definitive Feasibility Study for the Yangibana Rare Earths Project, revealing robust economics and a streamlined path to production with substantial infrastructure already in place.

Aquirian Limited reported a near tripling of EBITDA to $4.6 million in FY26, driven by a $48 million contract win for its Drillforce subsidiary and expanded production capacity at its Wubin facility.

Renascor Resources' cost study estimates its hydrofluoric acid-free purification method can produce battery-grade graphite at about US$459 per tonne, positioning it as a competitive ex-China alternative to conventional HF-based processes.

Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.

Amaero has resumed titanium powder production following a six-week safety-driven pause, implementing extensive facility and process upgrades to enhance operational safety and support future growth.

Qoria Limited marked a turning point in FY25, delivering 25% growth in Annual Recurring Revenue and a 684% jump in underlying EBITDA, setting sights on 20% EBITDA margin in FY26 amid global digital safety expansion.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.

The Federal Court has given the green light to Aura Consolidated Group’s takeover of Qoria Limited, setting the stage for a share suspension on ASX and the start of Aura CDIs trading next week.

Legend Mining advances gold exploration at its Pinnacle Well Project, confirming extensive hydrothermal alteration and coincident IP anomalies at Pyrophyllite Hill and Alpha North, with drilling set to follow heritage surveys.

Alterity Therapeutics has secured official FDA confirmation that a single pivotal Phase 3 trial, backed by prior Phase 2 data, can support approval of ATH434 for Multiple System Atrophy. Trial initiation remains on track for late 2026.

X2M Connect has landed a A$1.1 million contract to supply 50,000 additional personal safety devices to Seoul’s AI-powered smart city infrastructure, pushing contracted volumes to 150,000 and underpinning a strong start to FY27.

ClearVue Technologies has earned three international certifications for its Gen 3 Vision Glass, confirming its photovoltaic performance, safety, and durability across multiple product variants.